The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia

References

• WHOFact sheet on Hepatitis C2015 [updated 2015; cited 2016 June 22]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/.http://www.who.int/mediacentre/factsheets/fs164/en/Accessed June 22, 2016
   Google Scholar
• RazaviHWakedISarrazinCThe present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigmJ Viral Hepat201421Suppl 1345924713005
   PubMed Web of Science ®Google Scholar
• YounossiZMOtgonsurenMHenryLInpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United StatesJ Viral Hepat201522213714524813350
   PubMed Web of Science ®Google Scholar
• GentileIBuonomoARZappuloEBorgiaGInterferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?Expert Rev Anti Infect Ther201412776377324918116
   PubMed Web of Science ®Google Scholar
• European Association for Study of LiverEASL Recommendations on Treatment of Hepatitis C 2015J Hepatol201563119923625911336
   PubMed Web of Science ®Google Scholar
• American Association for the Study of Liver DiseaseRecommendations for testing, managing, and treating hepatitis C2016 [updated 2016; cited]. Available from: http://www.hcvguidelines.orgAccessed August 10, 2016
   Google Scholar
• MyersRPShahHBurakKWCooperCFeldJJAn update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the LiverCan J Gastroenterol Hepatol2015291193425585348
   PubMed Web of Science ®Google Scholar
• IyengarSTay-TeoKVoglerSPrices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysisPLoS Med2016135e100203227243629
   PubMed Web of Science ®Google Scholar
• ZhangSBastianNDGriffinPMCost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the USBMC Gastroenterol2015159826239358
   PubMed Web of Science ®Google Scholar
• SaabSPariseHVirabhakSCost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the USJ Med Econ201619879580527063573
   PubMed Web of Science ®Google Scholar
• ChhatwalJKanwalFRobertsMSDunnMACost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United StatesAnn Intern Med2015162639740625775312
   PubMed Web of Science ®Google Scholar
• WongWKrahnMLeeKSinghSCADTH Therapeutic ReviewsDrugs for chronic hepatitis C infection: cost-effectiveness analysisOttawa, ONCanadian Agency for Drugs and Technologies in Health2016
   Google Scholar
• StahmeyerJTKrauthCBertFCosts and outcomes of treating chronic hepatitis C patients in routine care – results from a nationwide multicenter trialJ Viral Hepat201623210511526411532
   PubMed Web of Science ®Google Scholar
• StahmeyerJTRossolSKrauthCOutcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antiviralsJ Comp Eff Res Epub2015511
   Web of Science ®Google Scholar
• LeTKKalsekarAMacaulayDTreatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevirJ Manag Care Spec Pharm201521430831825803764
   PubMed Web of Science ®Google Scholar
• NybergLChiangKLiZNybergAYounossiZCheethamTSu1047 resource utilization during hepatitis C treatment with boceprevir or telaprevir-based triple therapy vs dual therapy in a large health maintenance organizationGastroenterology20141465 Suppl 1S-973
   Web of Science ®Google Scholar
• Australian Society for Infectious DiseasesAustralian recommendations for the management of hepatitis C virus infection: a consensus statement 20162016 [updated 2016; cited 2016]. Available from: https://www.asid.net.au/documents/item/1208Accessed January 30, 2017
   Google Scholar
• AfdhalNZeuzemSKwoPION-1 InvestigatorsLedipasvir and sofosbuvir for untreated HCV genotype 1 infectionN Engl J Med2014370201889189824725239
   PubMed Web of Science ®Google Scholar
• NelsonDRCooperJNLalezariJPALLY-3 Study TeamAll-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with genotype 3 infection: ALLY-3 phase III studyHepatology20156141127113525614962
   PubMed Web of Science ®Google Scholar
• Australian Government Department of HealthThe Pharmaceutical Benefits ScheduleAustralia2016 [updated 2016; cited 2016]. Available from: www.pbs.gov.auAccessed November 12, 2016
   Google Scholar
• Australian Government Department of HealthThe Medicare Benefits ScheduleAustralia2016 [updated 2016; cited]. Available from: http://www.health.gov.au/Accessed November 12, 2016
   Google Scholar
• JacobsonIMMcHutchisonJGDusheikoGADVANCE Study TeamTelaprevir for previously untreated chronic hepatitis C virus infectionN Engl J Med2011364252405241621696307
   PubMed Web of Science ®Google Scholar
• PoordadFMcConeJJrBaconBRSPRINT-2 InvestigatorsBoceprevir for untreated chronic HCV genotype 1 infectionN Engl J Med2011364131195120621449783
   PubMed Web of Science ®Google Scholar
• MannsMPMcHutchisonJGGordonSCPeginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialLancet2001358928695896511583749
   PubMed Web of Science ®Google Scholar
• YounossiZMParkHGordonSCReal-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis CAm J Manag Care2016226 Spec NoSP205SP21127266950
   PubMed Web of Science ®Google Scholar
• MessinaJPHumphreysLFlaxmanAGlobal distribution and prevalence of hepatitis C virus genotypesHepatology2015611778725069599
   PubMed Web of Science ®Google Scholar
• SapraSChangEBroderMSL’ItalienGIncidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort studyBMC Health Serv Res20141442925249187
   PubMed Web of Science ®Google Scholar
• SolomonMBonafedeMPanKDirect medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patientsDig Dis Sci201156103024303121717127
   PubMed Web of Science ®Google Scholar
• JonkYCAdeniyiTKnottADieperinkEWHoSBInterferon-based therapies for hepatitis C: utilization, costs, and outcomesAm J Pharm Benefits2013512533
   Google Scholar
• AroraSThorntonKMurataGOutcomes of treatment for hepatitis C virus infection by primary care providersN Engl J Med2011364232199220721631316
   PubMed Web of Science ®Google Scholar